Skip to content

Study · Animal study (in vivo) · horse · 2013

3 results

Comparison of Efficacy of Two Dose Rates of Histrelin for Inducing Ovulation in Broodmares

Kiser AM, Sudderth AK, Brinsko SP, Burns PJ, Douglas RH, Blanchard TL

Journal of equine veterinary science1 Oct 2013Cited by 3 (Europe PMC)

DOI10.1016/j.jevs.2012.12.007 (opens in a new tab)PepBankPUB-94614986
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In histrelin-treated mares, ovulation within 2 days did not differ between maiden/barren (96%) and foaling mares (86%; P > .10).

    In plain wordsIn mares receiving histrelin, ovulation within 2 days did not differ between maiden/barren mares and foaling mares.

    Peptide
    Histrelin
    Outcome
    No significant changeOvulation within 2 days by reproductive status
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    Foaling mares
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 or 0.5 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    No differences in proportion of maiden plus barren (96%) compared to foaling (86%) mares ovulating within 2 days was found (P > .10); therefore, responses for all mares were combined for analysis.
    1 context sentence
    Summary · context
    On Tuesday or Thursday, mares in estrus with uterine edema, a relaxed cervix, and a dominant follicle ≥30-mm diameter were alternately assigned to treatment with 0.5 mg of intramuscular (IM) histrelin (group 1) or 0.25 mg IM histrelin (group 2).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mares, ovulation within 2 days did not differ between 0.5 mg histrelin (42 of 46, 91%) and 0.25 mg (44 of 52, 85%; P > .10).

    In plain wordsIn mares, ovulation within 2 days did not differ between 0.5 mg and 0.25 mg histrelin.

    Peptide
    Histrelin
    Outcome
    No significant changeOvulation within 2 days
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    0.25 mg histrelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    No differences in ovulation rates within 2 days were noted for 0.5 mg histrelin compared to those for 0.25 mg histrelin treatment (42 of 46, 91%; 44 of 52, 85%; P > .10).
    1 context sentence
    Summary · context
    On Tuesday or Thursday, mares in estrus with uterine edema, a relaxed cervix, and a dominant follicle ≥30-mm diameter were alternately assigned to treatment with 0.5 mg of intramuscular (IM) histrelin (group 1) or 0.25 mg IM histrelin (group 2).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mares, monthly response rates did not differ between 0.5 and 0.25 mg histrelin (P > .10).

    In plain wordsIn mares, monthly ovulation responses did not differ between 0.5 and 0.25 mg histrelin.

    Peptide
    Histrelin
    Outcome
    No significant changeMonthly ovulation response
    Study

    horsen: not reported in source

    Broodmares in estrus
    Comparator
    0.25 mg histrelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.5 mg · intramuscularAs given in this study (horse).

    Source sentences

    Summary
    No differences were detected between response rates to 0.5 or to 0.25 mg histrelin for any month (P > .10).
    1 context sentence
    Summary · context
    On Tuesday or Thursday, mares in estrus with uterine edema, a relaxed cervix, and a dominant follicle ≥30-mm diameter were alternately assigned to treatment with 0.5 mg of intramuscular (IM) histrelin (group 1) or 0.25 mg IM histrelin (group 2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.